WellAve Dermatology Launches In-House Pathology Services for Faster, Personalized Skin Diagnoses
Faster, More Reliable Results
With WellAve's new pathology services, patients will now receive diagnostic results in under 48 hours, a substantial improvement from the previous two-week timeline. By bringing these services in-house, WellAve ensures that its dermatology providers have direct access to a dedicated dermatopathologist who can consult on complex cases in real-time, offering a more precise and timely diagnosis.
"Our goal has always been to deliver the best care possible to our patients," said Dr.
Partnership with AnnaPath Pathalogy Services
The new service is a collaboration between WellAve Dermatology and AnnaPath Pathalogy Services, a
"This new collaboration allows us to combine local expertise with specialized dermatological insight," said
A Patient-Centered Approach
WellAve Dermatology's new pathology service will benefit patients at no additional cost, as it is fully covered by the insurance plans already accepted by the practice. With faster diagnostic times, patients gain peace of mind, especially when awaiting potentially serious results, such as skin cancer diagnoses. This reduction in wait time can be reassuring, helping patients feel supported through what can be a stressful period.
"The time from biopsy to diagnosis is critical," noted
Comprehensive Expertise
About WellAve Dermatology
WellAve Dermatology is a leading provider of medical dermatology services, dedicated to delivering high-quality, patient-focused care. With offices across
Press Contact:
COO
WellAve Dermatology
[email protected]
www.wellave.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/wellave-dermatology-launches-in-house-pathology-services-for-faster-personalized-skin-diagnoses-302294970.html
SOURCE WellAve Dermatology
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Operata deepens Observability across AI to human agents - launching the control layer for CX
- Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
- Morphy Richards Showcases 90 Years of Smart Ideas at IFA Berlin 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share